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ABSTRACT Modulation of the growth rate in Mycobacterium tuberculosis is key to
its survival in the host, particularly with regard to its adaptation during chronic in-
fection, when the growth rate is very slow. The resulting physiological changes influ-
ence the way in which this pathogen interacts with the host and responds to antibi-
otics. Therefore, it is important that we understand how the growth rate impacts
antibiotic efficacy, particularly with respect to recovery/relapse. This is the first study
that has asked how growth rates influence the mycobacterial responses to combina-
tions of the frontline antimycobacterials, isoniazid (INH), rifampin (RIF), and pyrazin-
amide (PZA), using continuous cultures. The time course profiles of log-transformed
total viable counts for cultures, controlled at either a fast growth rate (mean genera-
tion time [MGT], 23.1 h) or a slow growth rate (MGT, 69.3 h), were analyzed by the
fitting of a mathematical model by nonlinear regression that accounted for the dilu-
tion rate in the chemostat and profiled the kill rates and recovery in culture. Using
this approach, we show that populations growing more slowly were generally less
susceptible to all treatments. We observed a faster kill rate associated with INH than
with RIF or PZA and the appearance of regrowth. In line with this observation, re-
growth was not observed with RIF exposure, which provided a slower bactericidal
response. The sequential additions of RIF and PZA did not eliminate regrowth. We
consider here that faster, early bactericidal activity is not what is required for the
successful sterilization of M. tuberculosis, but instead, slower elimination of the bacilli
followed by reduced recovery of the bacterial population is required.
KEYWORDS Mycobacterium tuberculosis, antagonism, antibiotic combinations,
bactericidal activity, chemostat culture, growth rate, isoniazid, mathematical
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Improvement in tuberculosis (TB) treatment with the aim of shortening the period ofantibiotic therapy without increasing relapse rates or encouraging the development
of antibiotic-resistant strains is urgently needed (1). Although new combinations of
antibiotics with novel modes of action are being evaluated, the optimal dosing and
treatment duration can be investigated further for existing antibiotics. Understanding
how the growth rate impacts the activity of frontline antibiotics so that they can be
delivered using an alternative approach or in a different timely fashion can contribute
to the development of regimens that contain a combination of both conventional and
new antibiotics (2–5).
One of the requirements of a new antibiotic combination is its ability to target
heterogeneous populations of bacteria, particularly those that develop antibiotic tol-
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erance during the course of treatment and that are thought to contribute to relapse
posttreatment (6). Fluctuations in the growth rate in Mycobacterium tuberculosis enable
the organism to adapt to different environmental niches in the host, particularly with
regard to its adaptation during chronic infection, when the growth rate becomes very
slow. The resulting genotypic and phenotypic changes influence the way in which this
pathogen interacts with the host and responds to antibiotic treatment. Therefore, it is
important that we understand how growth rate impacts antibiotic efficacy. The current
paradigm concerning the effect of growth rate or growth phase on the response of M.
tuberculosis to antibiotic therapy relies heavily upon the notion that fast-growing
bacteria are more susceptible to the action of antibiotics than slow growers (7–10). The
slow-growing proportion of the M. tuberculosis population is thought to be refractory
to the bactericidal action of antituberculosis antibiotics due to phenotypic tolerance
and persistence through treatment (10). Informative in vitro evaluations using batch
models have determined the activity of antibiotics against relevant phenotypes, in-
cluding nonreplicating persistent bacteria (11–14). However, it is challenging to dissect
out the direct cause and effect of a single stimulus in batch cultures. The only models
that can be used to determine the effects of the growth rate on drug responses are
controlled and defined continuous cultures in chemostats (14–17). These growth
systems enable us to control the growth rate with minimal changes to the physio-
chemical environment, thereby allowing the effects of different growth rates to be
compared. In this study, we investigated the contribution of growth rate to early
bactericidal kill and the regrowth/recovery of the bacterial population when exposed to
isoniazid (INH), pyrazinamide (PZA), and rifampin (RIF), delivered singly or in combina-
tion. To enable us to perform these analyses, we have derived a mathematically
discriminative approach for the analyses of drug responses in chemostat culture which
accounts for dilution effects and provides predictive and quantitative insights from the
bacterial responses.
RESULTS
The antibiotics INH, RIF, and PZA were added during culture steady state at the MICs
to replicate cultures for each single antibiotic or antibiotic combination at each growth
rate, except for the triple combination, for which a single culture was performed at each
growth rate. A static concentration of antibiotic was maintained in culture throughout
each time course. Viable counts were performed throughout the culture time courses
and for a minimum of 14 mean generation times (MGT), which is equivalent to 970.2 h
and 322.2 h for slow growth and fast growth, respectively. The time course profiles of
the log-transformed viable counts for each culture were analyzed with the fitting of a
mathematical model by nonlinear regression, where parameters representing gradients
on the logarithmic scale were determined for each culture to describe the logarithmic
transformation of the viable count profile over time. These overall gradients comprise
an estimated knet rate constant parameter that accounts for the net bacterial death/
regrowth and a fixed kchemo rate constant imposed by the chemostat culture according
to fast growth or slow growth conditions (equations 1 and 2). A minimum of at least
one gradient is needed to describe a log viable count profile: the initial  gradient,
typically indicating a bactericidal or a bacteriostatic response, where  is equal to
(knet_  kchemo). If more than the  gradient is needed to adequately describe the log
viable count profile (i.e., if more than one exponential phase is present), then additional
gradient parameters are estimated accordingly, where  is equal to (knet_  kchemo).
Additional gradients indicate responses other than the initial net kill, e.g., regrowth/
recovery at a faster net growth rate, net kill at a rate different from that initially
observed, or a reestablished steady-state growth. The knet_, and knet_ elimination rate
constants were compared between pairs of culture conditions to determine the impact
of the growth rate in each treatment case, while accounting for the chemostat dilution
rate, kchemo, for each growth rate (Table 1). P values from pairwise Z-tests comparing
relevant pairs of experiments were calculated (Table 2) to determine which growth
rate-specific responses were significantly different.
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The rate of kill was higher in fast-growing M. tuberculosis. Early bactericidal
activity was observed in all cultures (as shown by negative knet_ kill rate constants;
Table 1), except for bacteriostatic responses to single RIF exposures in slow growers
(where knet_ was close to 0; Fig. 1i). Slow-growing cultures exposed to INH at the MIC,
either singly or in combination (Fig. 1g, j, and k), all showed initial killing rates similar
to each other (with knet_ values ranging from 0.03 to 0.04). Apart from the results
obtained with the RIF-INH-PZA triple combination (knet_  0.036 and 0.01 for slow
growth and fast growth, respectively), the fast growers showed an initial net bacterial
killing rate of a greater magnitude than the slow growers for any given antibiotic
therapy. Fast growers or slow growers exposed to RIF alone (Fig. 1c and i) and fast
growers exposed to the triple combination (Fig. 1e) demonstrated monophasic elimi-
nation over time, with the kill rates being lower than those for all INH- and INH-RIF-
exposed cultures (Fig. 1a, d, g, and j; Table 1).
The further addition of PZA to the RIF-INH combination in a slow-growing culture
(Fig. 1k) resulted in a kill rate similar to that of INH used singly (Fig. 1g) and the RIF-INH
TABLE 1 Values for knet_, knet_, and knet_ (if present) with the percent error for slow-growing or fast-growing continuous cultures of
Mycobacterium tuberculosis exposed to INH, RIF, and PZA, singly and in combination
Treatment
Slow-growing continuous cultures (kchemo  0.01) Fast-growing continuous cultures (kchemo  0.03)
knet_ (h1) knet_ (h1) knet_ (h1) knet_ (h1) knet_ (h1) knet_ (h1)
Est.a % RSE Est. % RSE Est. % RSE Est. % RSE Est. % RSE Est. % RSE
RIF 0.0001b 288b 0.020 26
INH 0.041 52 0.013 10 0.118 47 0.033 7
RIF and INH 0.030 19 0.013 22 0.102 18 0.029 37
RIF, INH, and PZA 0.036 55 0.007 44 0.010 38
INH at 16 MIC 0.110 35 0.003 13 0.014 4 0.104 19 0.009 69 0.037 6
Control 0.013 9.12 0.031 4.3
aEst., estimate.
bThe knet_ estimate is very close to 0; i.e., the overall observed  elimination rate of the viable count is approximately equal to the kchemo washout rate, leading to
an inflated relative standard error of this estimate.
TABLE 2 P values for pairwise comparisons of knet_ in fast-growing and slow-growing
continuous cultures of M. tuberculosis exposed to MICs of INH, RIF, and PZA singly and in
combinationa
Pairwise comparison P value
knet_ comparisons
RIF, slow vs fast 0.01
INH, slow vs fast 0.20
RIF-INH, slow vs fast 0.02
RIF-INH-PZA, slow vs fast 1.34
INH at 16 MIC, slow vs fast 1.00
RIF vs INH, slow 0.84
RIF vs RIF-INH, slow 0.01
INH vs RIF-INH, slow 1.34
RIF vs INH, fast 0.08
RIF vs RIF-INH, fast 0.01
INH vs RIF-INH, fast 0.80
RIF-INH vs RIF-INH-PZA, slow 1.28
RIF-INH vs RIF-INH-PZA, fast 0.01
INH vs INH at 16 MIC, slow 0.12
INH vs INH at 16 MIC, fast 0.81
RIF vs RIF-INH-PZA, slow 0.06
INH vs RIF-INH-PZA, slow 1.11
RIF vs RIF-INH-PZA, fast 0.49
INH vs RIF-INH-PZA, fast 0.07
knet_ and knet_ comparison
RIF-INH vs RIF-INH-PZA, slow 1.18
aFast-growing continuous cultures (fast) had an MGT of 23.1 h, and slow-growing continuous cultures (slow)
had an MGT of 69.3 h. knet_ comparisons were also made for 16 MIC INH, and knet_ and knet_
comparisons were made for responses that were triphasic.
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dual combination (Fig. 1j) (P  1.11 and 1.28, respectively), indicating that there were
no additional killing benefits by the addition of PZA. However, when making a
similar comparison in a fast-growing culture, the kill rate for RIF-INH-PZA (Fig. 1e)
was lower than that for the double combination (Fig. 1d) and INH single treatment
(Fig. 1a) (knet_  0.01 for the triple combination versus knet_  0.1 [P  0.07 for
FIG 1 Viability of M. tuberculosis growing under a fast growth rate (MGT, 23.1 h) (a to f) or a slow growth rate (MGT, 69.3 h) (g to l)
in continuous culture and exposed to either INH at 0.5 mg ml1 (a, g), INH at 8 mg liter1 (b, h), RIF at 0.032 mg liter1 (c, i), INH at
0.5 mg liter1 and RIF at 0.032 mg liter1 (d, j), INH at 0.5 mg liter1, RIF at 0.032 mg liter1, and PZA at 250 mg liter1 (e, k), or no
antibiotic as a control (f, l). Total viable counts (number of log10 CFU per milliliter; circles) were determined by plating; the
mathematical model, governed by the estimated knet_/ and intercept parameters (solid black line), was fitted to the data; and the
underlying imposed chemostat washout rate (gray dashed line) was used as a comparison.
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INH, P  0.01 for RIF-INH]), indicating that the further addition of PZA to the fast-
growing population reduced the beneficial effects of INH killing. This was indicative of
a potential antagonistic effect between INH-RIF and PZA.
Increasing the INH concentration does not eliminate regrowth. Increasing the
exposure of INH from the MIC to a 16-fold higher MIC (8 mg liter1, a concentration
more reflective of patient serum levels in the clinic) gave rise to a faster initial killing
rate in slow-growing cultures (knet_, 0.041 versus 0.110 [P  0.12] for the MIC
versus 16 MIC, respectively) (Fig. 1g and h). However, the concentration increase
made little difference to the initial killing rate in fast-growing cultures (knet_, 0.118
versus 0.104 [P  0.81] for the MIC versus 16 MIC, respectively) (Fig. 1a and b),
perhaps suggesting that the kill rate for INH at the MIC is maximal for fast-growing
bacteria and indicating that fast-growing bacteria are more susceptible to INH. The
responses to 16 MIC INH exposure were also the only trends that followed a triphasic
profile, with two distinguishable initial bactericidal phases, indicating that the higher
INH concentration provoked a response in the bacterial population different from that
provoked by INH at the MIC. As discussed above, in all four of these situations (fast or
slow culture with the MIC or 16 MIC INH), a regrowth/recovery phase was observed,
with the regrowth rate being approximately equivalent in size to the dilution rate for
each culture, leading to relatively flat second and final phases to the viable count
profiles, implying a reestablishment of steady state. However, at the higher INH
concentration, for both growth rates, the apparent time of onset of the net regrowth/
recovery phase was later and occurred from a starting point of a lower viable count.
Regrowth in response to INH is not eliminated by PZA and/or RIF. The addition
of RIF to INH did not alter the kill rate or the regrowth rate compared to the rates
achieved with INH alone for the fast growers or the slow growers. Regrowth in the
presence of the RIF-INH combination was apparent after 100 h postexposure in fast-
growing cultures (Fig. 1d) and after approximately 350 h in slow growers (Fig. 1j), with
knet_ values being 0.029 and 0.013, respectively. The addition of PZA in the triple
combination of PZA-RIF-INH eliminated regrowth in the fast-growth-rate culture (Fig. 1e). In
slow-growing cultures, there was a reduction in the regrowth rate (from knet_  0.013
to knet_  0.007). However, regrowth was not eliminated entirely. What was surprising
was a lack of a reduction in the kill rate in the slow-growth culture (Fig. 1k) with the
addition of PZA. These findings show that PZA appears to have more of an effect in
reducing the regrowth of fast-growing cultures than that of slow growers. The only
situation in which a combination containing INH did not result in regrowth was for the
fast-growing culture treated with RIF-INH-PZA. It is possible that the lower kill rate in
the fast growers exposed to the triple combination contributed to a lack of regrowth,
as this was also observed for RIF exposure, where the killing rate was also more gradual.
DISCUSSION
The rate of kill was faster in fast-growing M. tuberculosis. Apart from the triple
combination, for any given antibiotic treatment, there was a more rapid initial bacterial
killing in fast growers than in slow-growing cultures. It is widely accepted that bacteria
in stationary phase/nonreplicating phases are less susceptible in vitro to the frontline
antibiotics RIF and INH (12, 13, 18, 19). However, the effect of growth rate on the
effectiveness of drug combinations has never been looked at in M. tuberculosis and is
particularly important for organisms that can survive in the host for long periods of
time under slow-growing or nongrowing conditions, which are characteristic of TB
disease progression. Some of these studies have included the use of mathematical
models, which described three bacterial states, representing fast-multiplying, slow-
multiplying, and nonmultiplying bacteria, in order to identify the responses to antibi-
otics (12). These mathematical models have predicted exposure-response relationships
by inferring bacterial cell states within batch cultures, where interpretation of drug
responses was confounded by many factors other than growth rate. Continuous culture
provides an invaluable method for determining growth rate effects while controlling
other parameters in the system (14, 15, 17). A limitation of these systems is that the
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interpretation of bacterial responses is complicated by the continuous flow of medium
into the chemostat and the loss of cells in the effluent, particularly as this dilution rate
is different for the two growth rates. We have accounted for this limitation in the
mathematical model described here. Antibiotic activity in other bacteria is also im-
pacted by the growth rate, as shown in previous experiments using the chemostat, but
very few of these studies have used mathematical models to quantify and determine
the bacterial responses (16, 17, 20, 21). Levin and Udekwu (22) developed a quantitative
model framework, using parameter values from the literature (or best a priori esti-
mates), for generating simulations, hypotheses, and interpretations of bacterial re-
sponses in batch or continuous cultures. This model accounts for culture dilution rates
and the drug dilution rate (drug clearance in pharmacokinetic terms) and described
various considerations that could be incorporated into future experimental designs,
such as the effect of secondary resources from dead cells and metabolites that have
been released, wall subpopulations (biofilms), and the impact of reduced cell density
on the MIC. Other plausible mathematical models could be used to describe these
phenotypic responses and bacterial population dynamics. However, given that we
observed viable count data rather than any quantification of specific subpopulations
and antibiotic exposures were performed at one or two drug concentrations, more
complex mathematical models were not applied at this stage.
Increasing the concentration of INH does not remove regrowth. Exposure to INH
in the chemostat led to rapid bactericidal responses followed by regrowth/recovery,
and this was irrespective of the growth rate. Recovery in the chemostat was attributable
to a population of bacteria that either increased their growth rate or maintained a
growth rate that was dictated by the flow rate of the growth medium (14). These
experiments indicate that biexponential killing and persistence through INH exposure
in clinical or in vivo studies are not explained by a reduced growth rate. We previously
showed under both these growth rates that recovery was coincident with a substantial
increase in mutant frequency and that the bactericidal activity of INH was being
arrested, in part, by the emergence of katG resistance mutations and not a reduction
in the log-phase populations, irrespective of the growth rate (14, 23). This finding was
also reflected in another study by Gumbo et al., in 2007, using a hollow-fiber pharma-
codynamic model (24). However, we also showed that the response to INH alone is not
entirely explained by an increase in mutant frequency but is also explained by sub-
stantial genotypic changes that are growth rate specific (14). The biphasic kill observed
in M. tuberculosis-infected guinea pigs treated with INH was found to be associated
with the emergence of antibiotic-tolerant persisting populations that were not resistant
mutants (25). Similarly, relapse has previously been observed in mice after the cessation
of treatment. Of all treatment groups that included INH, at least 30% of the mice
relapsed (as defined by the isolation of M. tuberculosis from the spleen), whereas in
treatment groups without INH, tubercle bacilli could be isolated from only 8% of mice
(26). The lack of reduced recovery at higher concentrations has also been observed
previously over a range of INH concentrations both in vitro and in vivo (13, 27).
Addition of RIF and PZA does not eliminate the regrowth associated with INH.
Despite the response to RIF being slower and monophasic, it was unable to remove the
recovery elicited by INH when used in a combined exposure at either growth rate.
Similarly, a lower rate of kill by RIF has previously been shown in vitro and in mice, with
no relapse being observed (27). These findings were also reflected in a study by Hu et
al., in 2016, where RIF-containing regimens reduced persistence in mice (19). These
findings, combined with the fact that RIF has recently been shown to be effective at
higher doses, indicates that the removal of INH in treatment and the use of an
increased dose of RIF are worthy of investigation as attractive options for new drug
combinations (2, 28–30). It would be interesting to see if increasing the concentration
of RIF in our chemostat system leads to changes in the bacteriostatic versus bactericidal
response and whether this is growth rate specific or not. A murine study by Andries et
al. in 2010 ranked the bactericidal and sterilizing potencies of several regimens (and
individual antibiotics), and the comparison of the two ranks highlighted that bacteri-
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cidal activity is not predictive of sterilization (31). Their study also confirmed that RIF
possessed more sterilizing activity than expected from the bactericidal efficacy, further
emphasizing the need to move away from early bactericidal activity as a priority
measure of drug candidate potential. A new drug combination needs to have good
sterilizing potential for genuine clinical cure/efficacy, but prediction of this is challeng-
ing. Improved bacterial markers of drug-tolerant persistent subpopulations that can be
measured early in the development of a drug combination are required, and progress
has been made in this area (32). Our results also suggest that the addition of PZA in the
triple combination reduced the beneficial effects of INH killing of fast-growing bacteria,
indicating that there could be antagonism between PZA and INH in chemostat culture.
PZA could be bacteriostatic against the fast growers, resulting in a halt in replication,
which in turn reduced the fast killing effects of INH (33). It has been shown that growth
inhibition by bacteriostatic antibiotics is associated with suppressed cellular respiration,
whereas cell death from exposure to bactericidal antibiotics causes accelerated respi-
ration (34). A reduced cellular respiration induced by PZA exposure could be an
explanation for the antagonism observed between INH and PZA. It may be that the
slower INH killing of fast growers leads to a lack of regrowth. INH has also been shown
to have an antagonistic effect on the efficacy of PZA in mice (19, 27, 35, 36), providing
further support for the removal of INH either entirely or after an appropriate duration
of treatment, and it would therefore be interesting to see, using our continuous culture
models, whether the removal of INH after 1 to 2 days (with continued exposure to PZA
and RIF) reduces the presence of regrowth.
Concluding remarks. Regrowth is associated with the presence of INH and not the
bacterial growth rate. The association between INH and recovery/relapse, combined
with the knowledge that M. tuberculosis overcomes the effects of INH after an initial
killing phase by the development of resistance and/or drug tolerance in any in vitro or
in vivo model, supports the suggested replacement of INH with drugs that kill more
slowly and that do not lead to a relapse. The chemostat model and the method of data
analysis described here can contribute to the direct comparison of drug combinations
and provide information about the relationship between bactericidal activity and
recovery.
MATERIALS AND METHODS
Reagents. Primary stock solutions of RIF, INH, and PZA were prepared at 10 g liter1 in 100%
dimethyl sulfoxide. These were frozen in aliquots (100 l) at 20°C. A working stock of RIF was prepared
at 1 g liter1 (diluted from the 10-g liter1 stock using water) and was also frozen at 20°C. When
required, the stocks were diluted to the desired concentration in water and filter sterilized (0.2-m pore
size).
Strains and their growth. M. tuberculosis (strain H37Rv) was used in all experiments. Bacilli were
enumerated on 7H10 agar plus oleic acid-albumin-dextrose-catalase supplement.
Continuous culture of M. tuberculosis. M. tuberculosis (strain H37Rv) was grown in chemostats
under controlled conditions as described previously (14). We cultured M. tuberculosis using CAMR
Mycobacterium medium MOD2, which contains glycerol as the limiting nutrient (37). Continuous cultures
were performed at two different growth rates to steady state under defined and controlled conditions
at pH 6.9, at a temperature of 37°C, and at a dissolved oxygen tension of 10% (14). The cultures achieved
an MGT of 23.1 h (fast growth) or an MGT of 69.3 h (slow growth), where the fractional washout/
replacement rate of the medium in the continuous culture was 0.03 h1 and 0.01 h1, respectively.
Antibiotics were added during steady state at the MICs (0.5 mg liter1 of INH, 0.032 mg liter1 of RIF, and
250 mg liter1 of PZA) to two replicate cultures for each single antibiotic or antibiotic combination at
each growth rate except for the triple combination, where a single culture was performed at each growth
rate. A static concentration of antibiotic was maintained in culture throughout each time course. In the
case of INH, exposures to 16 MIC (8 mg liter1) were also assessed. Viable counts were performed
throughout the culture time courses and for a minimum of 14 MGT, which is equivalent to 970.2 h and
322.2 h for slow growth and fast growth, respectively (14). Further triplicate fast-growth or slow-growth
cultures were established without antibiotic exposure to provide baseline information about the
differences in viability between the two growth rates.
Viability measurements. The viability of the cultures was measured at each MGT using the viable
count method of Miles et al. (38) with the following modification: the plate was divided into quadrants
for the dilutions. In each quadrant, three 20-l aliquots of the appropriate dilution were spotted, and
then the plates were left to dry at room temperature. Colonies were counted after 3 weeks of incubation
at 37°C.
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Mathematical modeling. The growth rate, death rate, and chemostat washout rate (by continuous
culture) of a given population of M. tuberculosis in the continuous culture incubation were described
mathematically as first-order processes, i.e., processes where the rates of bacterial growth, death, or
chemostat elimination in the continuous culture at a given instant of time were all proportional to the
size of that population of M. tuberculosis at that given instant of time and governed by the first-order rate
constants kg, kd, and kchemo for the growth, death, and chemostat washout, respectively. When they were
combined, these component rates give an expression for the overall rate of change of the size of the M.
tuberculosis population (MTb) in log10 CFU ml1 (equation 1):
dMTb ⁄ dt  kg  MTb – kd  MTb – kchemo  MTb (1)
where t is time.
Equation 1 can be simplified as outlined in equation 2:
dMTb ⁄ dt  kg – kd – kchemo  MTb (2)
knet_ – kchemo  MTb
  MTb
Equation 2 summarizes that the rate of change of the M. tuberculosis population was governed by an
overall net first-order rate constant, , itself comprised of a net bacterial growth/death rate constant
(knet_) and the chemostat continuous fractional washout rate constant (kchemo; fixed to 0.01 h1 and 0.03
h1 for slow-growing or fast-growing cultures, respectively. Equation 2 (an ordinary differential equation)
was integrated into an exponential, closed-form solution describing the M. tuberculosis population as a
direct function of time and the initial size of the population (equation 3):
MTbtime  A  exp  time (3)
where A is the initial size of the M. tuberculosis population.
In this form,  is the gradient of a plot of the natural log transform of the count of the M. tuberculosis
population versus time or the apparent gradient of a plot of the M. tuberculosis population versus time
on a semilog scale and has units of time1. A is the y axis intercept of the same transformed profile/plot.
This mathematical approach allows for a more precise partitioning of the overall behavior of the bacterial
population over time (seen at the level of the raw data via the  rate constant) into the processes of
bacterial growth/death (governed by knet_) and the fixed, known, and experimentally controlled process
of the chemostat continuous culture washout (governed by kchemo). If it is apparent from a plot of the
logarithmic transformation of the observed viable count data that more than one exponential phase (i.e.,
more than one gradient on the log scale) is required to describe the observations, then equation 3 (and
its underlying assumptions) can be doubled up into a biexponential equation (equation 4).
MTbtime  A  exp  timeB  exp  time (4)
Here, B and  represent the initial value and the overall net first-order rate constant describing the
behavior of a 2nd subpopulation of M. tuberculosis contributing to the total observed viable count,
respectively. This second subpopulation may have had a slower or faster overall net growth or death rate
than the other and/or may have begun from a different initial starting point. This second subpopulation
may have contributed to potential regrowth that was not obvious until later in the time course or
perhaps to a second slower elimination phase under drug therapy. Further exponential terms (e.g., using
the parameters G and ) may be added if the data have extra phases able to support their estimation.
A schematic of the processes considered by the overall mathematical model in equation 4 applied in this
work is given in Fig. 2. The mathematical models of equation 3 or equation 4 were applied to the time
course profiles of viable counts from continuous culture to provide an estimate of the  elimination rate
and, if present, the  regrowth rate and/or their corresponding knet_ or knet_ values, given the known,
fixed kchemo washout rate constant. These parameter estimates compare net growth or elimination rates
between different experimental conditions and are used to simulate a line of best fit to provide a visual
FIG 2 A biexponential, two-state mathematical model applied to viable count data obtained from
continuous cultures of Mycobacterium tuberculosis that were treated with static concentrations of INH,
RIF, and PZA either singly or in combination. Total Mtb  MTb1  MTb2,   kg1  kd1  kchemo  knet_ 
kchemo,   kg2  kd2  kchemo, and kchemo  knet_  kchemo. kg, bacterial replication (growth); kd, bacterial
death; kchemo, bacterial washout due to dilution rate of chemostat. The sign and magnitude of knet
typically depend on A or , which governs the kill phase of antibiotic treatment, and B or , which
governs the regrowth phase of antibiotic treatment. A two-state model was adequate to describe the
data set profiles for most cultures. However, some cultures demonstrated single or triple exponential
phases and required either one state or three states for the data to be adequately described.
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check of how effectively the mathematical model describes the data. Observations of the minimum
viable count in culture were also compared to the initial value at the start of treatment to estimate an
observed maximum reduction in the viable count, to be used in conjunction with the mathematical
model parameter values estimated from the data to provide any extra insight into drug activity.
Parameter estimation from applying the model to the data used the nonlinear least-squares optimization
function lsqnonlin as part of the pracma package in the R statistical software language (version 3.4.2)
with an unweighted objective function. The standard errors (SE) of the parameter estimates were
calculated using the method outlined by Landaw and DiStefano, with the Jacobian of model parameter
sensitivities being estimated using a numerical central difference method (39). SE were expressed as a
percentage relative to the parameter estimate in question (percent relative standard error [RSE), with an
RSE of less than 50% being considered an acceptable degree of precision of an estimate, given the data
in question. The replicate experiments were treated as a naive pool for data analyses, rather than using
the average of replicate data at each time point (40). The significance of the differences between model
parameter estimates under different experimental conditions was examined with pairwise Z-tests.
Interpretation of knet_ and knet_ values. If gradients knet_, knet_, and knet_ were 0, then the
net rate of change of the M. tuberculosis population is negative and a plot of the M. tuberculosis
population viable count in the continuous culture versus time would show an exponential decrease over
time. This is the case for all negative knet values, knet equal to 0 (i.e., bacteriostasis), or any positive knet
values that are not large enough in magnitude to cancel out the imposed, fixed kchemo (i.e., net growth,
but not fast enough to completely overcome the chemostat washout rate). A negative gradient value is
therefore indicative of either bacteriostatic or bactericidal activity. If a gradient is equal to 0, then the net
rate of change of the M. tuberculosis population is zero and a plot of the population log viable count
versus time will be flat. For this situation, knet must equal (1)  kchemo. A gradient of 0 (or a value that
is very close to 0) indicates growth equal to the imposed rate of chemostat washout, as seen in the
steady-state control, no-drug cultures. Estimates of knet that are very close to 0 can show poor relative
standard error precision for the parameter estimate. If the gradient is 0, then the net rate of change of
the M. tuberculosis population is positive and a plot of the population viable count versus time shows an
exponential increase over time. For this, knet must be both positive and larger in absolute value than
kchemo. A positive gradient is therefore an indication of regrowth/recovery or of an M. tuberculosis
population in the overall culture.
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